Donate

Octapharma USA Announces FDA Approval of NUWIQ New Product Strengths

August 23, 2017

Note: The following is an edited version of a press release from Octapharma USA. Read the press release from Octapharma USA in it’s entirety here. Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved new product strengths for NUWIQ. The agency approved new single dose NUWIQ vial strengths of 2500, 3000 and 4000 International […]

Dear Addy: Biosimilars

November 9, 2015

Dear Addy, I keep hearing about biosimilars. What are they, and how do they differ from generic drugs? Sincerely, Curious About Products Hi Curious, Thanks for your question. A biosimilar is a pharmaceutical drug that is made to have similar active properties as a biological drug that has already been licensed. Biologics are really important […]

Infusing Love: Speed Bumps Along the Road to Independence

September 9, 2015

We are still on the road to self-infusion, and it’s been a long-term journey to his independence.  Benny, my 13-year-old who has severe hemophilia is stressed about doing his own needle stick. He is a particularly anxious kid and determinedly marches to his own beat, so letting him infuse at his own pace is the […]

Infusing Love: Factoring in the Freak Out

September 2, 2015

It is a common refrain to hear medical professionals comment on how well Logan does with his infusions. This is usually echoed in a, “He is such a champ,” or “How did you get to be so brave,” or the sadder version, “I wish my older patients were this good.” I am proud of Logan; […]

Dear Addy: 340B Programs

April 7, 2015

Dear Addy, The specialty pharmacy that I have to use through my insurer doesn’t carry my preferred brand of factor so I have to go through the prior authorization process to get my factor. My hemophilia treatment center (HTC) does not have a 340B program but I know of another HTC that does and they […]

New Gene Therapy For Hemophilia Shows Potential As Safe Treatment

March 12, 2015

Research showed that bleeding events were drastically decreased in animals with Hemophilia B. Using a viral vector to swap out faulty genes proved safe and could be used for the more common Hemophilia A. _______________________________ A multi-year, ongoing study suggests that a new kind of gene therapy for Hemophilia B could be safe and effective […]

Biogen Idec and Sobi See Progress in Pediatric Hemophilia B Study

February 27, 2015

This is an edited version of a press release from Biogen Idec. To read the full release, please click here. ____________________ Biogen Idec  and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under […]

Dear Addy: COBRA and the ACA

February 23, 2015

Dear Addy: It used to be when you left or lost your job you could get COBRA coverage until you found a new job. What is happening to COBRA with ACA implementation? What happens now if I lose my job and need health insurance? Sincerely, Daniel, Hemophilia Patient ___________________________________ Dear Daniel, If you lose your […]

Baxter Reports Data from Extended Half-Life Study

February 13, 2015

Baxter International Inc. presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland. The […]

FDA To Review CSL Behring’s New Long-Lasting Hemophilia B Product

February 4, 2015

CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Upon FDA approval, rIX-FP will provide hemophilia B patients with a long-acting treatment option with dosing intervals up […]

Dear Addy: Specialty Pharmacy vs. PBM

January 12, 2015

Dear Addy, What is the difference between a Specialty Pharmacy and a Pharmacy Benefits Manager (PBM), and why should I care? Signed, John, young adult with mild hemophilia A ________________________________________________ Dear John, The Academy of Managed Care Pharmacy (AMCP) defines a specialty pharmacy as “…distinct from traditional pharmacies in coordinating many aspects of patient care […]

Determined to Become a “Runner”

January 5, 2015

It is important for individuals with bleeding disorders to participate in some form of physical activity.  Being physically active helps to strengthen one’s muscles, bones and joints.  Having a strong healthy body can be a reduction in the number of bleeding episodes an individual might experience.  Many in the bleeding disorders community are championing the […]

My Journey: Determined to Heal

December 9, 2014

For women carrying the hemophilia gene, getting a proper diagnosis is not easy. By definition, if a woman has clotting factor levels less than 50%, she has mild hemophilia. Many women report that medical professionals are still under the assumption that a bleeding disorder can only affect males. It is these challenges that can make […]

Dear Addy: Max Out-of-Pocket

September 1, 2014

Note: This article was updated on 11/10/2015 to reflect 2016 out of pocket maximum limits.   Dear Addy, I’m a confused individual with private health insurance. I read that under the Affordable Care Act (ACA) the maximum annual out-of-pocket cost for health care is $6,850.00 for an individual. My insurance company is moving my factor […]

Infusing Love: Factor Where?!?!

July 2, 2014

I’ve given factor in the back of a moving car, at the beach while on vacation, and even in a tent while camping.  When most parents start learning to give factor, they learn at their kitchen table, or at the Hemophilia Treatment Center (HTC).  Like most parents, a nurse began giving my son his factor […]

1983—CDC Holds Summit on AIDS

March 17, 2014

In January 1983, the Centers for Disease Control gathered doctors, scientists, and representatives from the pharmacological industry and the bleeding disorders community in an attempt to find the means for halting the spread of AIDS. They were unable to arrive at a conclusion. During this meeting, Dr. Donald Francis of the CDC stood up, pounded […]

Biogen’s Hemophilia Drug Meets Late-stage Trial Goal

October 4, 2012

(Reuters) – Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia B, a rare inherited blood disorder that impairs coagulation, met the main goal of controlling bleeding in a late-stage trial. A single injection of the long-lasting clotting factor, being developed in partnership with Swedish Orphan Biovitrum, controlled bleeding in 90.4 […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.